Is the BAT Inhibition Able to Replace Sting Challenges? (BATIRS)
Study Details
Study Description
Brief Summary
Insect venom allergy is the major cause for severe allergic reactions in Europe. Wasps and honeybees are responsible for the majority of these allergic reactions. Symptoms range from generalized skin symptoms (wheals, swellings) to respiratory or cardiovascular problems such as asthma, dizziness, loss of consciousness, or cardiac arrest. The regular administration of insect venom ('venom immunotherapy') over up to 5 years is a well-established therapy, providing long-term protection from further systemic sting reactions in the majority of patients. However, there is no laboratory test which is able to identify patients who will still react to an insect sting. The only reliable method available is stinging patients with living insects ('sting challenges'). The key issue is that only few centers in Europe perform sting challenges and many patients have no access to these tests. Therefore, it is of utmost importance to find a method which is able to identify patients who are still at risk for future allergic sting reactions.
The inhibition of the basophil activation test (BAT) could be a potential method to monitor the effectiveness of immunotherapy. Basophils are cells which are activated in acute allergic reactions. The basophil activation of blood donors with vespid venom allergy can be measured after adding sera from allergic patients undergoing immunotherapy. In a preliminary study we found that the activation of basophils could be inhibited in all patients treated with vespid venom, however, results must be confirmed in a larger study.
In this study, a total of 219 patients with vespid venom allergy will be included. Those patients who are receiving or who have already finished venom immunotherapy will be sting challenged and blood samples will be taken to perform BAT inhibition experiments. At the same time, donors with confirmed vespid venom allergy, who have not undergone immunotherapy, will be recruited for a blood donation, which is necessary for the BAT inhibition tests.
If results of the preliminary study could be confirmed, the BAT inhibition will facilitate monitoring the effectiveness of venom immunotherapy and patients would benefit from an early detection of lacking tolerance and consequently from the increased venom dose preventing future life threatening systemic sting reactions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: early maintenance phase patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged |
Diagnostic Test: sting challenge
At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
|
| Active Comparator: maintenance phase patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged |
Diagnostic Test: sting challenge
At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
|
| Active Comparator: after stopping VIT patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged |
Diagnostic Test: sting challenge
At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
|
| Other: blood donors patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test) |
Other: blood donation
To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
|
Outcome Measures
Primary Outcome Measures
- Outcome sting challenge vs. BAT Inhibition test [4 hours]
The primary endpoint for the study is the inhibition of the CD63 basophil response (BAT inhibition at a concentration of 11ng/ml) in vespid venom allergic patients. A minimum activation of 25% is required to see sufficient inhibition of basophil activity. Immunotherapy will be considered successful if the BAT inhibition (with added serum) is reduced by at least 80% compared to 'no serum'.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Legally competent male and female subjects who are currently treated or who have been treated with vespid venom immunotherapy
-
Age ≥18 and ≤70 years
-
Written consent of the participant after being informed
Exclusion Criteria:
-
Pregnancy
-
Autoimmune disease
-
Uncontrolled cardiovascular disease
-
Uncontrolled asthma
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Dermatology and Venerology, Medical University of Graz | Graz | Austria | 8036 |
Sponsors and Collaborators
- Medical University of Graz
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 30-381 ex 17/18 (BATIRS)